Investigational ER degrader safe, with early signs of antitumour activity against advanced ER-positive breast cancer

ASCO GU 2015 news roundup

Adjuvant treatment with sorafenib or sunitinib does not improve outcomes in localised renal carcinoma

Combination of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma

Docetaxel with androgen deprivation therapy combo in hormone-naïve metastatic prostate cancer

Combination of abiraterone and cabazitaxel in metastatic castration-resistant prostate cancer

Is there a role for androgen deprivation therapy combined with radiotherapy in intermediate risk prostate cancer?

When and whether to conduct endocrine therapy in non-metastatic prostate cancer

Optimizing survival in advanced prostate cancer: Welcome and introduction

Optimizing survival in advanced prostate cancer: Understanding PC heterogeneity to guide treatment choices

Optimizing survival in advanced prostate cancer: Tailoring mCRPC therapies to optimise survival

Optimizing survival in advanced prostate cancer: CHAARTED: What are the implications for the future?